logo-loader
viewZacks Small-Cap Research

Zacks Small-Cap Research: combination therapies taking over as next generation in immuno-oncology

Zacks Small-Cap Research Senior Biotechnology Analyst John Vandermosten sat down with Proactive at the Biotech Showcase 2020 in San Francisco. Vandermosten explained how combination therapies are taking over as the next generation in immuno-oncology.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 5 hours ago

2 min read